BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.78%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.01B
AUM Growth
+$7.01B
(+1.7%)
Cap. Flow
-$225M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12
Top Buys
| 1 |
Eli Lilly
LLY
|
$39.6M |
| 2 |
Evolent Health
EVH
|
$38.1M |
| 3 |
Merck
MRK
|
$34.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$27.1M |
| 5 |
Humana
HUM
|
$26.3M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$53.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$51.1M |
| 3 |
HCA Healthcare
HCA
|
$43.5M |
| 4 |
Intuitive Surgical
ISRG
|
$43.3M |
| 5 |
Boston Scientific
BSX
|
$42.1M |
Sector Composition
| 1 | Healthcare | 99.05% |
| 2 | Industrials | 0.87% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$100B
| $386M | 5.51% | 1,097,166 -48,529 | -4% | -$17.1M |
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $385M | 5.49% | 9,380,300 -131,600 | -1% | -$5.4M |
|
3
argenx
ARGX
$43.6B
| $360M | 5.13% | 923,284 +36,356 | +4% | +$14.2M |
|
|
4
Intuitive Surgical
ISRG
$170B
| $288M | 4.11% | 842,224 -126,562 | -13% | -$43.3M |
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $246M | 3.51% | 2,612,800 -500 | -0% | -$47.2K |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $203M | 2.89% | 3,201,800 -66,200 | -2% | -$4.19M |
|
7
Moderna
MRNA
$9.37B
| $185M | 2.64% | 1,525,059 -26,647 | -2% | -$3.24M |
|
8
Abbott
ABT
$231B
| $180M | 2.56% | 1,646,501 -415 | -0% | -$45.2K |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $171M | 2.44% | 899,650 +16,400 | +2% | +$3.12M |
|
10
Incyte
INCY
$16.5B
| $164M | 2.34% | 2,640,765 -199,735 | -7% | -$12.4M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $146M | 2.09% | 3,114,375 +24,375 | +0.8% | +$1.15M |
|
12
Stryker
SYK
$150B
| $146M | 2.08% | 476,946 -7,828 | -2% | -$2.39M |
|
|
13
Boston Scientific
BSX
$156B
| $144M | 2.05% | 2,661,452 -778,127 | -23% | -$42.1M |
|
14
Revolution Medicines
RVMD
$7.1B
| $127M | 1.81% | 4,746,000 -1,900 | -0% | -$50.8K |
|
15
Medtronic
MDT
$119B
| $124M | 1.77% | 1,410,492 +181,257 | +15% | +$16M |
|
16
Inspire Medical Systems
INSP
$2.77B
| $116M | 1.65% | 357,020 -20,048 | -5% | -$6.51M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $114M | 1.62% | 4,013,500 | – | – |
|
|
AXNX
18
DELISTED
Axonics, Inc. Common Stock
AXNX
| $112M | 1.6% | 2,223,418 +311,557 | +16% | +$15.7M |
|
|
19
Evolent Health
EVH
$1.12B
| $104M | 1.49% | 3,448,322 +1,257,175 | +57% | +$38.1M |
|
20
UnitedHealth
UNH
$281B
| $101M | 1.44% | 210,127 +15,316 | +8% | +$7.36M |
|
21
Pacific Biosciences
PACB
$393M
| $100M | 1.43% | 7,542,829 +516,723 | +7% | +$6.87M |
|
22
Edwards Lifesciences
EW
$47.8B
| $97.9M | 1.4% | 1,038,092 -2,577 | -0.2% | -$243K |
|
23
DexCom
DXCM
$29.5B
| $97.9M | 1.4% | 761,716 +6,637 | +0.9% | +$853K |
|
24
Exact Sciences
EXAS
$8.98B
| $94.5M | 1.35% | 1,006,772 -218,270 | -18% | -$20.5M |
|
25
Insulet
PODD
$23.9B
| $93.3M | 1.33% | 323,594 | – | – |
|